GERN News and Press, Geron Corporation

2026-03-03 09:00:27 ET Next-generation cellular therapies and regenerative medicine drive exponential expansion New York, NY – March 3, 2026 – Market News Updates News Commentary – The global anti-aging therapy market is gaining serious momentum as peopl...

2026-02-26 14:08:41 ET Geron Overview The biotech sector ( XBI ) has lifted a lot of boats recently—and Geron ( GERN ) is arguably one of them. Despite RYTELO’s commercial troubles, which I have outlined since the beginning, Geron’s stock has outperforme...

2026-02-25 12:17:59 ET Geron Corporation (GERN) Q4 2025 Earnings Call February 25, 2026 8:00 AM EST Company Participants Dawn Schottlandt - Senior Vice President of Investor Relations & Corporate Affairs Harout Semerjian - CEO, President & Director Ahmed El...

2026-02-25 09:27:09 ET Image source: The Motley Fool. Wednesday, February 25, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-25 09:25:32 ET More on Geron Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade) Geron: From Launch Hype To Later-Line Gravity Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines Geron mi...

2026-02-25 07:04:04 ET More on Geron Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade) Geron: From Launch Hype To Later-Line Gravity Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines Geron Q4...

Achieved $48 million and $184 million in RYTELO ® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and tota...

HCI Group Inc. (HCI) is expected to report $4.87 for Q4 2025 XPEL Inc. (XPEL) is expected to report $0.43 for Q4 2025 Oversea-Chinese Banking Corporation Limited ADR (OVCHY) is expected to report $0.56 for Q4 2025 UMH Properties Inc. (UMH) is expected to report $0.24 for Q4 2025 I...

2026-02-24 10:09:43 ET More on Geron Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade) Geron: From Launch Hype To Later-Line Gravity Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines Geron fo...

FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following invest...